tiprankstipranks

Mark Saad Insider Profile

4 Followers
Mark Saad, CFO at Plus Therapeutics, holds 10.10K shares in Axsome Therapeutics (Ticker: AXSM), holds 13.75K shares in Catheter Precision (Ticker: VTAK), holds 276.86K shares in Plus Therapeutics (Ticker: PSTV). Most recently, Mark Saad Bought ― shares of Axsome Therapeutics on Nov 19, 2021 for an estimated value of 113.91K.
tipranks
Mark Saad

Mark Saad
Plus Therapeutics (PSTV)
CFO

Ranked #18,247 out of 98,564 Corporate Insiders

Profitable Transactions

100%
2 out of 2 Profitable Transactions

Average Return

+141.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$1M
61.74%
37.74%
0.52%
A breakdown of Mark Saad's holdings

Insider Roles

Axsome Therapeutics
(AXSM)
Director
Plus Therapeutics
(PSTV)
CFO
Catheter Precision
(VTAK)
Director
Roles that Mark Saad holds in companies

Most Profitable Insider Trade

Stock:
Axsome Therapeutics
(AXSM)
Rating:Informative Buy
Date:May 24, 2019 - May 24, 2020
Return:+227.10%
The most profitable trade made by Mark Saad

Mark Saad's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Plus Therapeutics
Feb 04, 2013
CFO
Uninformative Sell
$451.28K
Axsome Therapeutics
Nov 19, 2021
Director
Informative Buy
113.91K
$738.25K
Catheter Precision
Jan 07, 2021
Director
Uninformative Buy
$6.26K
List of latest transactions for each holding click on a transaction to see Mark Saad's performance on stock

Mark Saad insider profile FAQ

What is the percentage of profitable transactions made by Mark Saad?
The percentage of profitable transactions made by Mark Saad is 100%.
    What is the average return per transaction made by Mark Saad?
    The average return per transaction made by Mark Saad is 141.90%.
      What stocks does Mark Saad hold?
      Mark Saad holds: PSTV, AXSM, VTAK stocks.
        What was Mark Saad’s latest transaction?
        Mark Saad latest transaction was an Informative Buy of $113.91K.
          What was Mark Saad's most profitable transaction?
          Mark Saad’s most profitable transaction was an Informative Buy of AXSM stock on May 24, 2019. The return on the trade was 227.10%.
            What is Mark Saad's role in Plus Therapeutics?
            Mark Saad's role in Plus Therapeutics is CFO.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.